Cetera Investment Advisers
TXG icon

Cetera Investment Advisers’s 10x Genomics TXG Stock Holding History

Cetera Investment Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
38,587
+10,396
+37% +$272K ﹤0.01% 2668
2026
Q1 		$598K Buy
28,191
+359
+1% +$7.18K ﹤0.01% 3340
2025
Q4 		$454K Buy
27,832
+376
+1% +$5.68K ﹤0.01% 3519
2025
Q3 		$321K Buy
27,456
+12,703
+86% +$166K ﹤0.01% 3770
2025
Q2 		$171K Sell
14,753
-9,238
-39% -$84.2K ﹤0.01% 3765
2025
Q1 		$209K Buy
23,991
+4,093
+21% +$51.6K ﹤0.01% 3571
2024
Q4 		$286K Buy
19,898
+3,679
+23% +$58.1K ﹤0.01% 3154
2024
Q3 		$366K Buy
16,219
+5,453
+51% +$113K ﹤0.01% 2901
2024
Q2 		$209K Buy
10,766
+2,289
+27% +$59.9K ﹤0.01% 3329
2024
Q1 		$318K Buy
+8,477
New +$372K ﹤0.01% 2980
2022
Q1 		– Sell
-1,439
Closed -$214K – 1998
2021
Q4 		$214K Buy
+1,439
New +$220K ﹤0.01% 1695

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cetera Investment Advisers's TXG Position: Q2 2026 in Review

Cetera Investment Advisers increased its 10x Genomics (TXG) stake by 37% in Q2 2026, buying an estimated $272K and bringing the position to 38,587 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2668.

Cetera Investment Advisers first reported a position in TXG in Q4 2021 and has held it in 11 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Cetera Investment Advisers held 38,587 shares of 10x Genomics worth $1.48M as of Q2 2026.
  • Cetera Investment Advisers bought 10,396 10x Genomics shares in Q2 2026, an estimated $272K.
  • 10x Genomics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2668 holding.
  • Cetera Investment Advisers first reported a position in 10x Genomics in Q4 2021 and has held it in 11 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.